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Abstract
Background: Psoriasis is a common chronic inflammatory disorder associated with much physical and
psychological comorbidity. There is currently no cure for psoriasis, and it is a disorder characterized by
alternating periods of relapse and remission. The effectiveness of current treatments, such as psoralen UVA
radiation therapy (PUVA), usually correlates with higher toxicity. Newer treatments that are effective, but less
harmful are needed. The excimer laser is a newer treatment option for psoriasis that has shown promising
effects. This review aims to determine the efficacy of the excimer laser compared to traditional PUVA therapy.
Methods: An exhaustive search of available medical literature was conducted using Medline-Ovid, CINAHL,
Evidence-Based Medicine Reviews Multifile, and Web of Science using the keywords: psoriasis, excimer laser,
and PUVA therapy. Relevant articles were then assessed for quality using GRADE.
Results: Two studies met inclusion criteria and were included in the systematic review. One randomized
controlled trial of 272 patients with psoriasis demonstrated comparable effectiveness in elimination of
psoriatic plaques between PUVA monotherapy and PUVA with additional excimer laser therapy. In addition,
they determined that the combination group required fewer treatments and thus received a reduced
cumulative UVA dose. Another small randomized controlled trial of 10 patients with palmoplantar psoriasis
also demonstrated equal effectiveness of topical PUVA and excimer laser therapy.
Conclusion: The available data suggest that PUVA and excimer laser therapies offer similar effectiveness in
clearing psoriatic lesions. However, there appear to be some inherent advantages to excimer laser therapy over
PUVA monotherapy. When combined with PUVA therapy, the excimer laser decreases the number of
treatments required for remission and therefore the total UVA dosage administered. The excimer laser also
does not require additional medications to be taken prior to treatment. Further study is necessary to
determine long-term efficacy and side effects of use, but currently this therapy appears promising as an option
in the treatment of psoriasis.
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Abstract   
Background: Psoriasis is a common chronic inflammatory disorder associated with much 
physical and psychological comorbidity. There is currently no cure for psoriasis, and it is a 
disorder characterized by alternating periods of relapse and remission. The effectiveness of 
current treatments, such as psoralen UVA radiation therapy (PUVA), usually correlates with 
higher toxicity. Newer treatments that are effective, but less harmful are needed. The excimer 
laser is a newer treatment option for psoriasis that has shown promising effects. This review 
aims to determine the efficacy of the excimer laser compared to traditional PUVA therapy. 
 
Methods: An exhaustive search of available medical literature was conducted using Medline-
Ovid, CINAHL, Evidence-Based Medicine Reviews Multifile, and Web of Science using the 
keywords: psoriasis, excimer laser, and PUVA therapy. Relevant articles were then assessed for 
quality using GRADE. 
 
Results:  Two studies met inclusion criteria and were included in the systematic review. One 
randomized controlled trial of 272 patients with psoriasis demonstrated comparable 
effectiveness in elimination of psoriatic plaques between PUVA monotherapy and PUVA with 
additional excimer laser therapy. In addition, they determined that the combination group 
required fewer treatments and thus received a reduced cumulative UVA dose. Another small 
randomized controlled trial of 10 patients with palmoplantar psoriasis also demonstrated equal 
effectiveness of topical PUVA and excimer laser therapy.  
 
Conclusion:  The available data suggest that PUVA and excimer laser therapies offer similar 
effectiveness in clearing psoriatic lesions. However, there appear to be some inherent 
advantages to excimer laser therapy over PUVA monotherapy. When combined with PUVA 
therapy, the excimer laser decreases the number of treatments required for remission and 
therefore the total UVA dosage administered. The excimer laser also does not require 
additional medications to be taken prior to treatment. Further study is necessary to determine 
long-term efficacy and side effects of use, but currently this therapy appears promising as an 
option in the treatment of psoriasis. 
 
Keywords:  psoriasis, excimer laser, PUVA therapy 
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The Efficacy of the 308 nm Excimer Laser in the 
Treatment of Psoriasis in Comparison to PUVA Therapy 
 
BACKGROUND 
 Psoriasis is a chronic inflammatory condition that affects about 2% of the population.
1  
 
The pathophysiology of the condition is not completely understood, but it is generally accepted 
that it is characterized by keratinocyte over-proliferation, which has been linked to a substance 
that is produced by T lymphocytes.
2
  This correlation is suggested by the fact that biopsies of 
skin affected by psoriasis have demonstrated proliferation and abnormal differentiation of 
keratinocytes, and infiltration of helper T-cells.
3
  As of yet, there is no cure for psoriasis and it is 
characterized by a pattern of relapse and remission. Depending on the severity and location, 
psoriasis can be very debilitating both physically and psychologically. For many patients, the 
erythema, scaling, and sloughing skin is a major cosmetic concern. The affected skin can also 
cause physical discomfort due to pruritic and/or painful lesions. When located on the hands 
and feet it can impair normal activities of daily living due to limited dexterity and mobility. 
Psoriasis has also been associated with an increased risk of depression, anxiety, and suicidal 
ideation.
4 
 Other comorbidities associated with psoriasis include cardiovascular disease,
5  
psoriatic arthritis, lymphoma, inflammatory bowel disease, and non-alcoholic fatty liver 
disease.
6
 
 Moderate to severe psoriasis has traditionally been treated with narrow-band 
ultraviolet B radiation (NB-UVB) or psoralen UVA therapy (PUVA).
7
  Psoralen, usually in the form 
of 8-methoxypsoralen (8-MOP), is a photosensitizing agent that can be ingested or applied 
7 
 
topically via a cream or bath followed by UVA exposure. In this treatment, the entire skin area 
of the body, including affected and unaffected skin, is exposed to the UVA rays.  
 The excimer laser is a relatively new therapy that has demonstrated success in treating 
psoriasis.
8
  The laser emits focused UVB light with a wavelength of 308 nm by means of xenon 
chloride gas. Ultraviolet B radiation is effective in treating psoriasis due to its ability to reduce 
keratinocyte proliferation and cause T cell apoptosis.
9
  Unique to the excimer laser, it is 
administered via a hand-held device that has a spot diameter of 14-30 mm. This feature offers 
the advantage of only exposing the affected skin to UV radiation while sparing unaffected 
skin.
10
  Asawanonda et al
11
 demonstrated that due to increased thickness, psoriatic plaques 
may withstand higher doses of UV radiation than the surrounding healthy skin. This allows for 
fewer treatments and a lower cumulative dose of UV radiation required to induce remission 
when compared to PUVA therapy. 
 The aim of this review is to determine the efficacy of the 308 nm excimer laser when 
compared to traditional PUVA therapy in the treatment of psoriasis.  
METHODS 
 An exhaustive search of available medical literature was conducted using Medline-Ovid, 
CINAHL, Evidence-Based Medicine Reviews Multifile, and Web of Science using the keywords: 
psoriasis, excimer laser, and PUVA therapy. The search in Web of Science was further focused 
by excluding vitiligo from the search using “not.” Reference lists were also reviewed for 
additional relevant articles and the available studies were then limited to the English language 
and human studies. The abstracts were then assessed for relevance. Articles included in this 
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review included primary research that compared excimer laser therapy to PUVA therapy in 
patients with psoriasis. Articles were excluded that dealt primarily with pediatric populations 
and that lacked a comparative group (Figure I). 
 Relevant articles were then assessed for quality utilizing the Grading of 
Recommendations, Assessment, Development, and Evaluation system (GRADE).
12
 
RESULTS 
 The initial search yielded 30 articles for review. After full article review, two randomized 
controlled trials
13,14
 were chosen that met inclusion criteria. 
 The first study by Trott et al
13
 was a randomized controlled trial that included 272 
hospitalized patients with severe psoriasis affecting >20% of the body surface area.  
Participants were excluded if they had received systemic antipsoriatic treatment within the 
previous 4 months, had used topical treatments and/or other types of phototherapy within the 
previous 2 weeks, had concomitant or previous malignant skin tumors, or were under the age 
of 18. Of the 272 participants, there were 162 men and 110 women with a mean age of 50 
years. The baseline demographic characteristics were similar between groups including the 
baseline Psoriasis Area and Severity Index score (PASI) (Appendix A). The control group of 123 
patients received PUVA monotherapy orally or via bath 4 times a week for up to 6 weeks. Oral 
PUVA therapy consisted of ingesting 8-MOP two hours prior to UVA irradiation and bath PUVA 
was accomplished by soaking in 8-MOP for 20 minutes prior to irradiation. The initial UVA dose 
was determined based on skin type and the minimum phototoxic dose (MPD) that was 
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determined prior to treatment. The treatment group of 149 patients received PUVA therapy 
with up to 4 additional excimer laser treatment sessions during the first two weeks of therapy. 
An excimer laser generating monochromatic light on the wavelength of 308 nm was used. Initial 
doses were determined depending on the participants’ skin types (I-VI). The dose was increased 
at the next treatment session if there was no significant erythema from the previous treatment. 
The outcomes measured were PASI reduction, cumulative UVA and UVB radiation doses, side 
effects, and reasons for discontinuing treatment. The PASI score was recorded by a non-blinded 
observer. Blinding was not feasible due to the multiple, small, focused areas of 
hyperpigmentation that were caused by the laser. The participants were further followed for 12 
weeks to determine time to relapse.  
 Trott et al
13
 determined that both treatment and control groups attained notable 
reductions in PASI scores; however, there was no significant difference between the two groups 
in regards to the reduction. Of the 256 participants that completed therapy, 67.3% of the 
PUVA-only group and 63.6% of the PUVA/excimer group achieved complete clearance (>90% 
reduction in PASI), 23.0% of the PUVA-only and 28.0% of the combination group reached partial 
clearance (>50% reduction in PASI), and 9.7% of the PUVA-only and 8.4% of the combination 
group had slight improvement (<50% reduction in PASI). In regards to the cumulative UVA dose, 
they learned that there was significantly reduced exposure in the PUVA/excimer group 
compared to PUVA monotherapy. In the PUVA-only group the cumulative dose was 53.2 ±26.3 
J/cm
2
 while in the PUVA/excimer group it was 22.9 ± 5.8 J/cm
2
. There was also a significant 
decrease in the number of treatment sessions and the total duration of therapy required to 
achieve clearance. The PUVA-only group required a mean of 27 ± 7 sessions over 6.5 weeks 
10 
 
while the PUVA/excimer group only required 15 ± 6 sessions over 4.2 weeks. A total of 16 
participants (7 in PUVA-only and 9 in PUVA/excimer) dropped out due to inadequate time 
available for therapy. There were no drop-outs due to adverse side effects. The side effects that 
were observed were moderate erythema, hyperpigmentation, and blistering in both groups. 
During the 12 week follow-up period, fewer patients relapsed in the combination group versus 
the PUVA-only group (13 vs. 18), but it was not a significant difference. 
 The second study performed by Neumann et al
14
 was a randomized controlled trial with 
a left-right trial design. Ten participants with palmoplantar psoriasis were recruited (6 men and 
4 women with a mean age of 47 years). Participants were excluded if they had used topical 
treatments within the past month, or if they had received photochemotherapy or systemic 
antipsoriatic treatment in the past. In this trial, each patient served as their own control and 
each was randomly assigned to receive cream PUVA on one side and excimer laser therapy on 
the contralateral side.  On one side, psoralen was administered topically in cream form one 
hour before UVA irradiation, and on the contralateral side a 308 nm excimer laser was used 
after the minimum erythema dose (MED) was determined for each participant. The baseline 
right and left PASI scores were similar for each patient.  Each treatment was performed 4 times 
per week for 5 weeks. The outcome measures that were evaluated were the PASI score, which 
was measured by a blinded investigator, and adverse side effects. This study determined that 
both groups achieved a statistically significant decrease in PASI scores; however, there was not 
a significant difference between the two groups. In the PUVA group, the mean initial PASI score 
was 26.3 ± 19.6 and reduced to 9.3 ± 9.43 after 5 weeks of treatment. In the excimer laser 
group, the mean initial PASI score was 28 ± 18.74 and decreased to 10.2 ± 12.2 after the fifth 
11 
 
week. The side effects noted were erythema in three patients treated with the excimer laser 
and erythema and skin irritation in four patients treated with PUVA therapy. The 12-week 
follow-up period yielded 1 patient who relapsed at both sites. 
DISCUSSION 
 The available data from Trott et al
13
 and Neumann et al
14
 suggest that the use of the 
excimer laser in the treatment of psoriasis is as effective as PUVA therapy in clearing psoriatic 
plaques. However, it is difficult to ascertain the difference in efficacy between the two 
independent therapies from the information provided by Trott et al
13
 because the two 
therapies were not directly compared. Nevertheless, they were able to determine that the 
combination of the two therapies offers the advantage of leading to clearance of affected skin 
in a shorter amount of time, and with fewer treatments than PUVA monotherapy. This lessens 
the cumulative exposure to deeply penetrating and harmful UVA radiation. Prolonged use of 
PUVA monotherapy has been linked to an increased risk of squamous cell carcinoma due to the 
more vulnerable unaffected skin being exposed to UVA radiation. In a retrospective study by 
Lindelof et al,
15 
 they determined that patients treated with PUVA therapy had a 5-fold (men) 
and 3-fold (women) increase in the incidence of squamous cell carcinoma. The average follow-
up period was 16 years after PUVA therapy. Therefore, the combination therapy, with fewer 
treatments and lower UVA exposure, has the potential to result in a decreased risk of skin 
cancer, and provide increased patient satisfaction resulting in improved compliance with 
treatment. 
   
12 
 
 Conversely, the study by Neumann et al
14
 directly compares the two therapies. The 
information from this study suggests that even though the two therapies appear to be equal in 
their effectiveness in clearing psoriatic lesions, excimer laser therapy is easier to perform and 
does not require the use of topical or oral photosensitizing agents which have been associated 
with several adverse side effects. Topical use of these medications has been associated with 
acute phototoxic dermatitis or pruritus. Systemic use can cause nausea and pruritus and also 
necessitates the use of skin and eye protection from sunlight during and for an extended period 
following treatment.
 
Oral psoralen also carries a pregnancy category C rating
16
 and has been 
associated with an increase in low birth weight infants born to mothers who previously 
received systemic PUVA therapy.
17
  On the other hand, not much research is available regarding 
the use of the excimer laser and its safety during pregnancy. However, broadband UVB (BB-
UVB) treatment is currently the treatment of choice in pregnancy for severe disease as long as 
overheating is avoided.
18
  The excimer laser also emits UVB radiation, but has the added 
advantage of being more localized than BB-UVB. This could be a starting point to support the 
laser’s use in pregnant patients with psoriasis. 
One factor that could potentially create biased results is the lack of blinding of 
investigators in the study by Trott et al.
13 
 The investigators were recording the PASI scores as 
treatment progressed, and being aware of which treatment each patient was receiving creates 
the possibility of inadvertently altering the fairly subjective PASI score. 
 At this time, there is a need for larger randomized controlled trials comparing the 
excimer laser and PUVA therapy directly. The current research that was evaluated consists of a 
13 
 
fairly large study
13
 which did not compare PUVA and excimer laser therapy head-to-head, but 
as a combination therapy. The second study
14
 did compare PUVA and excimer directly, but had 
a very small population of only 10 patients. The current research on excimer laser therapy also 
lacks information regarding: adverse side effects associated with long-term use, long-term 
follow-up to determine duration of clearance, and relapse rates in comparison to other 
therapies. Presently, this long-term data is likely lacking due to the excimer laser being a 
somewhat new option in the treatment of psoriasis. See Table I. 
While cost and insurance coverage are other aspects of patient care that must be 
considered when deciding on a treatment plan for a particular patient, the current data 
demonstrates a potential for the excimer laser to become a principal modality in the treatment 
of psoriasis.  
CONCLUSION 
 To date, large randomized controlled trials evaluating the long-term effectiveness of the 
excimer laser compared to traditional PUVA therapy are lacking and further research is 
warranted. According to the GRADE criteria, the information gathered is of moderate quality 
due to the limitations discussed. Therefore, a weak recommendation can be made for the use 
of excimer therapy in the treatment of psoriasis. Nonetheless, due to the laser’s ability to 
selectively target affected skin and the ease of administration, the excimer laser shows promise 
as a safer and easier to use alternative to PUVA therapy for the treatment of moderate to 
severe psoriasis.  
14 
 
References 
1. Stern R, Nijsten T, Feldman S, Margolis D, Rolstad T. Psoriasis is common, carries a 
substantial burden even when not extensive, and is associated with widespread 
treatment dissatisfaction. Journal of Investigative Dermatology Symposium Proceedings. 
2004;9:136-139. 
2. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of 
human keratinocyte stem cell growth in short-term primary ex vivo culture. J Clin Invest. 
1995;95:317-327. 
3. Mendonca CO, Burden AD. Current concepts in psoriasis and its treatment. 
Pharmacology & Therapeutics. 2003;99:133-147 
4. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The Risk of Depression, anxiety, and 
suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol. 
2010;146:891-895. 
5. Pietrzak A, Bartosinska J, Chodorowska G, Szepietowski JC, Paluszkiewicz P, Schwartz RA. 
Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol. 2013;52:153-162. 
6. Onumah N, Kircik LH. Psoriasis and Its Comorbidities. Journal of Drugs in Dermatology. 
2012;11:S5-S10. 
7. Spuls P, Bossuyt P, van Everdingen J, Witkamp L, Bos J. The development of practice 
guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol. 
1998;134:1591-1596. 
8. Gattu S, Rashid RM, Wu JJ. 308-Nm Excimer laser in psoriasis vulgaris, scalp psoriasis, 
and palmoplantar psoriasis. Journal of the European Academy of Dermatology and 
Venereology. 2009;23:36-41. 
9. Krueger J, Wolfe J, Nabeya R, et al. Successful ultraviolet-B treatment of psoriasis is 
accompanied by a reversal of keratinocyte pathology and by selective depletion of 
intraepidermal T-cells. J Exp Med. 1995;182:2057-2068. 
10. Bonis B, Kemeny L, Bor Z, Szabo G, Ignacz F, Dobozy A. 308 nm excimer laser for 
psoriasis. J Invest Dermatol. 1998;110:702-702. 
11. Asawanonda P, Anderson RR, Chang Y, Taylor CR. 308 nm excimer laser for the 
treatment of psoriasis: a dose-response study. Arch Dermatol. 2000;136:619-624. 
12. GRADE working group. GRADE website. http://gradeworkinggroup.org/. Accessed 
August 26, 2013. 
13. Trott J, Gerber W, Hammes S, Ockenfels H. The effectiveness of PUVA treatment in 
severe psoriasis is significantly increased by additional UV 308-nm excimer laser 
sessions. European Journal of Dermatology. 2008;18:55-60. 
14. Neumann N, Mahnke N, Korpusik D, Stege H, Ruzicka T. Treatment of palmoplantar 
psoriasis with monochromatic excimer light (308-nm) versus cream PUVA. Acta Derm 
Venereol. 2006;86:22-24. 
15. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up 
study. Br J Dermatol. 1999;141:108-112. 
15 
 
16. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of 
psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2011;65:137-174. 
17. Gunnarskog J, Kallen A, Lindelof B, Sigurgeirsson B. Psoralen photochemotherapy 
(PUVA) and pregnancy. Arch Dermatol. 1993;129:320-323. 
18. Tyler KH, Zirwas MJ. Pregnancy and dermatologic therapy. J Am Acad Dermatol. 
2013;68:663-671. 
19. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. 
Dermatologica. 1978;157:238-244
16 
 
Table I. Characteristics of Reviewed Studies 
Quality Assessment 
    Downgrade Criteria 
Quality  
Study Design  Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Trott et al¹³ RCT Serious limitationsa No serious indirectness  No serious imprecision No serious inconsistencies Not likely  Moderate 
Neumann et al¹ RCT Serious limitationsa No serious indirectness  Serious imprecisionb No serious inconsistencies Not likely  Low 
aBoth studies lack patient allocation concealment, Trott et al13 also lacks blinding of  investigator 
bSmall sample size of 10 participants  
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Figure I. Flow Diagram of Study Selection 
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Appendix A. Psoriasis Area and Severity Index (PASI) 
The Psoriasis Area and Severity Index
19 
was developed as a standardized method of 
quantifying the severity and extent of a patient’s psoriasis. The score ranges from 0-72 with 
higher scores indicating more severe disease.  
Intensity and surface area are calculated for 4 body areas: head/neck, which is 
considered 10% of the body, arms (20%), trunk (30%), and legs (40%). Surface area is scored on 
a 7 point scale for each area: (0) 0%, (1) 1-9%, (2) 13-29%, (3) 30-49%, (4) 50-69%, (5) 70-89%, 
and (6) 90-100%. The intensity of erythema, induration, and desquamation are each rated on a 
5 point scale for each of the 4 body areas: (0) none, (1) mild, (2) moderate, (3) severe, and (4) 
very severe. 
E.g. Total body with most severe psoriasis: 
Head: 6 (4+4+4) x 10% =    7.2 
Arms: 6 (4+4+4) X 20% =   14.4 
Trunk: 6 (4+4+4) X 30% =  21.6 
Legs: 6 (4+4+4) X 40% =  + 28.8        
             72 
 
 
